相关实验视频

Updated: May 20, 2025

Comparative Analysis of Human Growth Hormone in Serum Using SPRi, Nano-SPRi and ELISA Assays

Comparative Analysis of Human Growth Hormone in Serum Using SPRi, Nano-SPRi and ELISA Assays

Published on: January 7, 2016

长效生长激素治疗儿科生长激素缺乏症的长效生长激素

Norbert Albers¹, Sarah Cadarette², Ben Feakins²

¹Department of Pediatric Endocrinology, Christliches Kinderhospital, Osnabrueck 49074, Germany.

Journal of the Endocrine Society

|March 27, 2025

概括

长效生长激素 (LAGH) 治疗儿科生长激素缺乏症 (GHD) 的疗效不同. 在网络元分析中,洛纳佩格索马托与每日索马托和索马卡西坦相比,显示出更好的生长结果.

科学领域:

内分泌学在内分泌学.
儿科儿科儿科
药理学药理学是指药理学的学科.

背景情况:

长效生长激素 (LAGH) 为生长激素缺乏症 (GHD) 提供了潜在的坚持和结果改进,而不是每日索马特罗宾.
LAGHs在分子上是不同的,具有独特的药理动力学/药理动力学特性,影响有效性和安全性.
洛纳佩格索马热是美国和欧洲唯一提供未经修改的索马热的LAGH.

研究的目的:

进行系统的文献审查和网络元分析,比较LAGHs在儿科GHD中的相对有效性和安全性.
为了评估可用的LAGHs与每日索马热的生长结果和安全概况.

主要方法:

贝叶斯网络元分析包括五个试验,其中三个为基础案例网络做出贡献.
三种LAGHs (lonapegsomatropin,somapacitan,somatrogon) 与每日索马热素的比较.
评估年化身高速度,身高标准偏差分数 (SDS) 变化,胰岛素样生长因子-1 (IGF-1) SDS变化,骨年龄进展和严重不良事件 (SAE).

主要成果:

洛纳佩格索马托在52周显示了统计学上显著的更高的年均身高速度和身高SDS变化,而不是每天服用索马托和索马卡西坦.
索马特龙和洛纳佩格索马特罗宾在52周的IGF-1 SDS变化明显高于某些比较剂;所有IGF-1 SDS都保持在正常范围内.
在骨年龄与年代年龄比率的进展或不同治疗方法的SAE中没有发现显著差异.

结论:

在这个网络元分析中,洛纳佩格索马托是唯一与改善生长结果相关的LAGH.
在严重不良事件中没有发现显著差异,尽管其他安全结果需要进一步分析.
由于LAGH的独特特性,需要仔细考虑小儿GHD治疗的疗效和安全性.

关键词:

文献审查文献审查长效生长激素是长效的生长激素.这是一个元分析.儿科生长激素缺乏症儿科生长激素缺乏症

更多相关视频

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

Mechanical and Controlled PRP Injections in Patients Affected by Androgenetic Alopecia

Mechanical and Controlled PRP Injections in Patients Affected by Androgenetic Alopecia

Published on: January 27, 2018

相关概念视频

Insulin: Dosing Regimen and Adverse Effects

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...

Hypoglycemia and Glucagon

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...

Insulin Formulations: Types and Delivery

Insulin Formulations: Types and Delivery

Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...